Erasca, Inc. (ERAS)
NASDAQ: ERAS · Real-Time Price · USD
15.30
-0.17 (-1.10%)
Mar 9, 2026, 1:44 PM EDT - Market open
Erasca Employees
Erasca had 103 employees as of December 31, 2024. The number of employees decreased by 23 or -18.25% compared to the previous year.
Employees
103
Change (1Y)
-23
Growth (1Y)
-18.25%
Revenue / Employee
n/a
Profits / Employee
-$1,239,670
Market Cap
4.74B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103 | -23 | -18.25% |
| Dec 31, 2023 | 126 | -3 | -2.33% |
| Dec 31, 2022 | 129 | 6 | 4.88% |
| Dec 31, 2021 | 123 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,769 |
| PTC Therapeutics | 991 |
| Amicus Therapeutics | 511 |
| TG Therapeutics | 399 |
| CRISPR Therapeutics AG | 393 |
| Mirum Pharmaceuticals | 372 |
| Apogee Therapeutics | 261 |
| CG Oncology | 142 |
ERAS News
- 4 days ago - Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat - GlobeNewsWire
- 13 days ago - Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 - GlobeNewsWire
- 4 weeks ago - Erasca to Present at Upcoming Conferences in February - GlobeNewsWire
- 6 weeks ago - Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday? - Benzinga
- 6 weeks ago - Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 6 weeks ago - Erasca Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewsWire
- 6 weeks ago - Erasca Announces Proposed Public Offering of $150 Million of Common Stock - GlobeNewsWire
- 2 months ago - Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones - GlobeNewsWire